Tag Archive for: Venture Capital

Sofinnova Partners promotes Javier Nunez-Vicandi to Partner, strengthening its Digital Medicine strategy

Physician-investor and co-builder of Sofinnova’s AI platform Sofia joins the partnership, underscoring the firm’s growing interest in healthtech and techbio PARIS, France – November 2, 2026 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, today announced the promotion of Javier Nunez-Vicandi to Partner. He […]

Sofinnova Partners closes oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies

The new fund extends Sofinnova’s 20-year track record of company creation with capacity to launch six to eight new ventures across Europe and the US PARIS, France – September 28, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of […]

Sofinnova Partners launches collaboration with AWS to scale AI across life sciences innovation

Sofinnova combines its sector expertise with AWS’s AI and cloud services to help life sciences companies scale faster The collaboration expands Sofinnova’s proprietary AI platform, Sofia, including a new founder-facing version PARIS, France – June 10, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, […]

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer Financing supports Ona’s transition […]

Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startups

Delivers high-performing AI infrastructure through NVIDIA DGX Cloud Lepton to portfolio companies, creating a powerful competitive advantage in $100B+ life sciences market BioCorteX, Bioptimus, Cure51, and Latent Labs among first cohort of startups to gain GPU capacity credits, helping position Europe at forefront of AI-driven drug discovery revolution PARIS, France – June, 11, 2025 – […]

© Optimum Strategic Communications.